DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Fareston (Toremifene Citrate) - Summary

 
 



FARESTON SUMMARY

FARESTON (toremifene citrate) Tablets for oral administration each contain 88.5 mg of toremifene citrate, which is equivalent to 60 mg toremifene.

FARESTON is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.


See all Fareston indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Fareston (Toremifene)

At 2014 San Antonio Breast Cancer Symposium three new Myriad studies highlighted
Source: Breast Cancer News From Medical News Today [2014.12.13]
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced results from a new study that demonstrated the ability of the myRisk™ Hereditary Cancer test to detect 105 percent more mutations in cancer...

Capecitabine No Benefit in Elderly Breast Cancer Patients
Source: Medscape Hematology-Oncology Headlines [2014.12.12]
The largest breast cancer trial to date of elderly patients found that single-agent capecitabine is no better than forgoing cytotoxic treatment altogether.
Medscape Medical News

New Algorithm for Treatment of Premenopausal Breast Cancer
Source: Medscape Hematology-Oncology Headlines [2014.12.12]
Results from the Suppression of Ovarian Function Trial (SOFT) are practice changing for a subgroup of premenopausal women with breast cancer.
Medscape Medical News

Ovarian suppression reduces recurrence for some young breast cancer patients
Source: Breast Cancer News From Medical News Today [2014.12.12]
The addition of ovarian suppression to adjuvant treatment (post-surgery) with tamoxifen reduced breast cancer recurrence in young women with hormone-sensitive early breast cancer who received...

Some ovarian and breast cancer patients may benefit from manipulation of a non-coding microRNA
Source: Breast Cancer News From Medical News Today [2014.12.12]
A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it is among the most frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.

more news >>

Published Studies Related to Fareston (Toremifene)

Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. [2013]
high-grade prostatic intraepithelial neoplasia (HGPIN) on biopsy... CONCLUSION: Although toremifene 20 mg did not lower the PCa detection rate, men

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2013]
therapy during a 2-year period... CONCLUSIONS: Toremifene significantly decreased the incidence of new vertebral

Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. [2011]
men younger than 80 years... CONCLUSIONS: Toremifene significantly decreased new vertebral fractures in men

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2010.10]
PURPOSE: Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period... CONCLUSIONS: Toremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. It also significantly improved bone mineral density, bone turnover markers and serum lipid profiles. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. [2010.07]
OBJECTIVE: Toremifene and tamoxifen have been used for adjuvant therapy in post-menopausal patients with breast cancer in Japan. Dyslipidemias are common in post-menopausal women. However, limited data are available on the effects of these agents on lipid profiles in Japanese patients. The Japan Toremifene Cooperative Study Group has been conducting a Phase III randomized trial of post-menopausal patients with breast cancer. One of its secondary endpoints is to confirm the effects of these agents on serum lipid profiles... CONCLUSIONS: Distinct differences between two selective estrogen receptor modulators on lipids were observed. Toremifene improved lipid profiles, particularly as an enhancer of high-density lipoprotein cholesterol. To a large extent, tamoxifen improved low-density lipoprotein cholesterol levels. The impact of these improved lipid profiles on the risk of cardiovascular diseases needs further confirmation.

more studies >>

Clinical Trials Related to Fareston (Toremifene)

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer [Terminated]
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene (FarestonŽ), to the single agent FDA-approved aromatase inhibitor letrozole (FemaraŽ) for the treatment of advanced breast cancer. The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of atamestane, plus toremifene (FarestonŽ), is more effective than letrozole (FemaraŽ) in delaying the growth of breast cancer.

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [Terminated]
The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (FarestonŽ), is more effective than another approved drug, letrozole (FemaraŽ), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.

The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia [Active, not recruiting]
The purpose of this study is to determine the effect of toremifene treatment to the MRI findings of the breast in women suffering from premenstrual mastalgia.

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer [Not yet recruiting]
The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer [Recruiting]

more trials >>

Reports of Suspected Fareston (Toremifene) Side Effects

Hepatic Function Abnormal (4)White Blood Cell Count Decreased (4)Interstitial Lung Disease (3)Hepatitis Acute (2)Condition Aggravated (2)Bronchiectasis (2)Diarrhoea (2)Respiratory Failure (2)Neoplasm Progression (1)Osteomyelitis (1)more >>


Page last updated: 2014-12-13

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014